Search Result

Results for "

mTORC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminoacyl-tRNA Synthetase (2) AMPK (5) Antibiotic (1) Antifolate (1) Apoptosis (15) Autophagy (30) Bacterial (3) c-Fms (1) DNA-PK (6) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (1) FKBP (2) Fungal (1) HIV (1) Influenza Virus (3) Isotope-Labeled Compounds (1) Kinesin (1) Mitophagy (2) mTOR (65) Phosphatase (1) PI3K (13) Pim (1) PKC (1) Prolyl Endopeptidase (PREP) (2) RABV (1) Ribosomal S6 Kinase (RSK) (1) ROR (1) Small Interfering RNA (siRNA) (2) ULK (1)
By Research Areas:	Cancer (71) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (6) Metabolic Disease (5) Neurological Disease (6)

By Targets:

Aminoacyl-tRNA Synthetase (2)

AMPK (5)

Antibiotic (1)

Antifolate (1)

Apoptosis (15)

Autophagy (30)

Bacterial (3)

c-Fms (1)

DNA-PK (6)

DNA/RNA Synthesis (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (1)

FKBP (2)

Fungal (1)

HIV (1)

Influenza Virus (3)

Isotope-Labeled Compounds (1)

Kinesin (1)

Mitophagy (2)

mTOR (65)

Phosphatase (1)

PI3K (13)

Pim (1)

PKC (1)

Prolyl Endopeptidase (PREP) (2)

RABV (1)

Ribosomal S6 Kinase (RSK) (1)

ROR (1)

Small Interfering RNA (siRNA) (2)

ULK (1)

By Research Areas:

Cancer (71)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (6)

Metabolic Disease (5)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114384B

NV-5138 hydrochloride 2 Publications Verification	mTOR	Neurological Disease
NV-5138 hydrochloride, a leucine analog, is the first selective and orally active brain *mTORC1* activator, binding to Sestrin2. NV-5138 hydrochloride is used for antidepressant studies .

HY-14581

Palomid 529

5 Publications Verification

P529
mTOR Apoptosis Cancer

Palomid 529 is a potent inhibitor of mTORC1 and mTORC2 complexes.

Palomid 529 5 Publications Verification P529	mTOR Apoptosis	Cancer
Palomid 529 is a potent inhibitor of *mTORC1* and *mTORC2* complexes.

HY-157167

mTORC1-IN-1	mTOR	Neurological Disease Cancer
mTORC1-IN-1 (T1) is a rapamycin homologue (rapalog) and selective *mTORC1* inhibitor. mTORC1-IN-1 regulates cell growth and metabolism and is implicated in a variety of diseases including cancer. mTORC1-IN-1 targets mTORC1 by binding to the FKBP12-FRB complex (docking score = −11.6 kcal/mol) .

HY-155475

mTORC1-IN-2	mTOR	Cardiovascular Disease
mTORC1-IN-2 (compound H3) is a NO donor compound that alleviates vasodilation and attenuates myocardial hypoxic injury. *mTORC1*-IN-2 upregulates TSC2-P expression and inhibits mTORC1 expression .

HY-15281

QL-IX-55

mTOR Cancer

QL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC₅₀s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively.

QL-IX-55	mTOR	Cancer
QL-IX-55 is a selective ATP-competitive inhibitor of *mTORC1/2* with IC₅₀s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively.

HY-132168

RMC-5552	mTOR	Cancer
RMC-5552 is a potent and selective *mTORC1* inhibitor. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC₅₀s of 0.14 nM and 0.48 nM, respectively. RMC-5552 shows much lower pAKT inhibition (IC₅₀ of 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold. RMC-5552 has anti-cancer activity .

HY-134904

RMC-6272 RM-006	mTOR	Cancer
RMC-6272 (RM-006) is a bi-steric *mTORC1*-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors .

HY-100026

PQR620

3 Publications Verification

mTOR Cancer

PQR620 is an orally bioavailable and selective brain penetrant inhibitor of mTORC1/2 .
HY-N2517

Dihydroevocarpine

mTOR Cancer

Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity .
HY-111065

OXA-01

mTOR Cancer

OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC₅₀ values of 29 nM and 7 nM, respectively .
HY-107363

FT-1518

mTOR Cancer

FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.
HY-50710

KU-0063794

10+ Cited Publications

mTOR Cancer

KU-0063794 is a potent and specific mTOR inhibitor, inhibiting both the mTORC1 and mTORC2 complexes with IC₅₀s of 10 nM.

PQR620 3 Publications Verification	mTOR	Cancer
PQR620 is an orally bioavailable and selective brain penetrant inhibitor of *mTORC1/2* .

Dihydroevocarpine	mTOR	Cancer
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the *mTORC1/2* activity .

OXA-01	mTOR	Cancer
OXA-01 is a potent *mTORC1* and *mTORC2* inhibitor, with IC₅₀ values of 29 nM and 7 nM, respectively .

FT-1518	mTOR	Cancer
FT-1518 is a new generation selective, potent and oral bioavailable *mTORC1* and *mTORC2* inhibitor, and exhibits antitumor activity.

KU-0063794 10+ Cited Publications	mTOR	Cancer
KU-0063794 is a potent and specific *mTOR* inhibitor, inhibiting both the *mTORC1* and *mTORC2* complexes with IC₅₀s of 10 nM.

HY-15247

Vistusertib 20+ Cited Publications AZD2014	mTOR Autophagy Apoptosis	Cancer
Vistusertib (AZD2014) is an ATP competitive *mTOR* inhibitor with an IC₅₀ of 2.81 nM. AZD2014 inhibits both *mTORC1* and *mTORC2* complexes.

HY-13806

XL388 3 Publications Verification	mTOR Autophagy	Cancer
XL388 is a highly potent and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 9.9 nM. XL388 simultaneously inhibits both *mTORC1* and *mTORC2*.

HY-100222

CZ415

3 Publications Verification

mTOR Cancer

CZ415 is a potent and highly selective mTOR inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.

CZ415 3 Publications Verification	mTOR	Cancer
CZ415 is a potent and highly selective *mTOR* inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits *mTORC1* and *mTORC2* protein complex.

HY-15248

GDC-0349 2 Publications Verification	mTOR Autophagy	Cancer
GDC-0349 is a potent and selective ATP-competitive *mTOR* inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both *mTORC1* and *mTORC2* complexes.

HY-16956

Onatasertib 2 Publications Verification CC-223; ATG-008	mTOR Apoptosis	Cancer
Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of *mTOR* kinase, with an IC₅₀ value for mTOR kinase of 16 nM. Onatasertib inhibits both *mTORC1* and *mTORC2*.

HY-P5984

Thioether-cyclized helix B peptide, CHBP	mTOR	Others
Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .

HY-10422

AZD-8055 40+ Cited Publications	mTOR Autophagy Apoptosis	Cancer
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive *mTOR* kinase inhibitor with an IC₅₀ of 0.8 nM. AZD-8055 inhibits both *mTORC1* and *mTORC2* .

HY-10474

Torkinib 15+ Cited Publications PP 242	mTOR Autophagy Mitophagy Apoptosis	Cancer
Torkinib (PP 242) is a selective and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 8 nM . PP242 inhibits both *mTORC1* and *mTORC2* with IC₅₀s of 30 nM and 58 nM, respectively .

HY-13003

Torin 1 60+ Cited Publications	mTOR Autophagy	Cancer
Torin 1 is a potent inhibitor of *mTOR* with an IC₅₀ of 3 nM. Torin 1 inhibits both *mTORC1/2 complexes with IC₅₀* values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy.

HY-18353

mTOR inhibitor-3 3 Publications Verification	mTOR	Cancer
mTOR inhibitor-3 is a remarkably selective *mTOR* inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses *mTORC1* and *mTORC2* in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.

HY-16962

CC-115 1 Publications Verification	DNA-PK mTOR	Cancer
CC-115 is a potent and dual DNA-PK and *mTOR* kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both *mTORC1* and *mTORC2* signaling.

HY-16962A

CC-115 hydrochloride 1 Publications Verification	DNA-PK mTOR	Cancer
CC-115 hydrochloride is a potent and dual DNA-PK and *mTOR* kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both *mTORC1* and *mTORC2* signaling.

HY-12652

AZD3147

mTOR Cancer

AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC₅₀ value of 1.5 nM. AZD3147 also has a selective effect on PI3K .

AZD3147	mTOR	Cancer
AZD3147 is a potent, orally active, selective dual inhibitor of *mTORC1* and *mTORC2* with an IC₅₀ value of 1.5 nM. AZD3147 also has a selective effect on PI3K .

HY-12513

Samotolisib 4 Publications Verification LY3023414	PI3K DNA-PK mTOR Autophagy	Cancer
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and *mTORC1/2* with IC₅₀s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits *mTORC1*/2 at low nanomolar concentrations .

HY-15272

WAY-600 5 Publications Verification	mTOR	Inflammation/Immunology Cancer
WAY-600 is a potent, ATP-competitive, and selective *mTOR* inhibitor with an IC₅₀ of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (mTORC1/2) assemble and activation.

HY-137175

TMBIM6 antagonist-1	mTOR	Cancer
TMBIM6 antagonist-1, a potential TMBIM6 antagonist, prevents TMBIM6 binding to mTORC2, decreases mTORC2 activity, and also regulates TMBIM6-leaky Ca ²⁺ .

HY-124798

Rheb inhibitor NR1 1 Publications Verification	mTOR	Neurological Disease Inflammation/Immunology Cancer
Rheb inhibitor NR1 is a Rheb inhibitor with an IC₅₀ of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven ^T389pS6K1 and increases the phosphorylation of ^S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity . ^{(Rheb-IVK: Rheb-dependent mTORC1 kinase activity)}

HY-120904

AMPK-IN-1

AMPK Metabolic Disease

AMPK-IN-1 is an activator of AMPK (EC₅₀: 551 nM for isoform α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1-independent way .

AMPK-IN-1	AMPK	Metabolic Disease
AMPK-IN-1 is an activator of AMPK (EC₅₀: 551 nM for isoform α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1-independent way .

HY-14530

Pelitrexol 1 Publications Verification AG 2037	Antifolate	Cancer
Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), a purine biosynthetic enzyme. Pelitrexol also inhibits *mTORC1* by reducing GTP-bound Rheb level, a *mTORC1* obligate activator. Pelitrexol shows robust tumor growth suppression in mice .

HY-10423

OSI-027 10+ Cited Publications ASP7486	mTOR Autophagy	Cancer
OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive *mTOR* kinase activity inhibitor with an IC₅₀ of 4 nM. OSI-027 targets both *mTORC1* and *mTORC2* with IC₅₀s of 22 nM and 65 nM, respectively .

HY-15174

Dactolisib Tosylate 45+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and *mTOR* kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits *mTORC1* and *mTORC2*.

HY-N0112

Dihydromyricetin 10+ Cited Publications Ampelopsin; Ampeloptin	mTOR Influenza Virus DNA/RNA Synthesis Autophagy	Infection Cancer
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-10219S

Rapamycin-d3 Sirolimus-d₃; AY-22989-d₃	mTOR FKBP Autophagy	Cancer
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

HY-111370

mTOR inhibitor-2	mTOR	Cancer
mTOR inhibitor-2 is a highlt potent, selective and oral *mTOR* inhibitor with an IC₅₀ of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates .

HY-10044

WYE-132 5+ Cited Publications WYE-125132	mTOR Apoptosis	Cancer
WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific *mTOR* kinase inhibitor (IC₅₀: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits *mTORC1* and *mTORC2*.

HY-10681

Gedatolisib 4 Publications Verification PKI-587; PF-05212384	PI3K mTOR	Cancer
Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and *mTOR* with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, *mTORC1* and *mTORC2* .

HY-143510

RMC-4627

mTOR Cancer

RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth.

RMC-4627	mTOR	Cancer
RMC-4627 is a selective *mTORC1* inhibitor that activates 4EBP1 and inhibits tumor growth.

HY-15271

WYE-687 3 Publications Verification	mTOR PI3K	Cancer
WYE-687 is an ATP-competitive *mTOR* inhibitor with an IC₅₀ of 7 nM. WYE-687 concurrently inhibits activation of *mTORC1* and *mTORC2. WYE-687 also inhibits PI3Kα* and PI3Kγ with IC₅₀s of 81 nM and 3.11 μM, respectively.

HY-P5984A

Thioether-cyclized helix B peptide, CHBP TFA	mTOR	Others
Thioether-cyclized helix B peptide, CHBP (TFA) is the TFA form of Thioether-cyclized helix B peptide, CHBP (HY-P5984). Thioether-cyclized helix B peptide, CHBP (TFA) can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .

HY-13002

Torin 2 10+ Cited Publications	mTOR DNA-PK Autophagy Apoptosis	Cancer
Torin 2 is an *mTOR* inhibitor with EC₅₀ of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC₅₀: 200 nM). Torin 2 also inhibits DNA-PK with an IC₅₀ of 0.5 nM in the cell free assay. Torin 2 can suppress both *mTORC1* and *mTORC2*.

HY-15271A

WYE-687 dihydrochloride	mTOR PI3K	Cancer
WYE-687 dihydrochloride is an ATP-competitive *mTOR* inhibitor with an IC₅₀ of 7 nM . WYE-687 dihydrochloride concurrently inhibits activation of *mTORC1* and *mTORC2* . WYE-687 also inhibits PI3Kα and PI3Kγ with IC₅₀s of 81 nM and 3.11 μM, respectively .

HY-119665

Asteltoxin

AMPK mTOR Cancer

Asteltoxin is an inhibitor for extracellular vesicles (EV), which exhibits inhibitory effects towards mitochondrial ATP synthase and mTORC1 activation .

Asteltoxin	AMPK mTOR	Cancer
Asteltoxin is an inhibitor for extracellular vesicles (EV), which exhibits inhibitory effects towards mitochondrial ATP synthase and mTORC1 activation .

HY-12034

WYE-354 5 Publications Verification	mTOR Autophagy Apoptosis	Cancer
WYE-354 is an ATP-competitive *mTOR* inhibitor with an IC₅₀ of 5 nM. WYE-354 also inhibits PI3Kα and PI3Kγ with IC₅₀s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both *mTORC1* and *mTORC2*. WYE-354 induces autophagy activation in vitro .

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks *mTORC2* as well as *mTORC1*.

HY-10297

Omipalisib 10+ Cited Publications GSK2126458; GSK458	PI3K mTOR Autophagy	Cancer
Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity .

HY-10115

PI-103 15+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 is a potent PI3K and *mTOR* inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, *mTORC1, and mTORC2. PI-103 also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 induces autophagy .

HY-10115A

PI-103 Hydrochloride 15+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 Hydrochloride is a dual PI3K and *mTOR* inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, *mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .

HY-12868

Bimiralisib 3 Publications Verification PQR309	PI3K mTOR	Cancer
Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I *PI3K/mTOR* inhibitor with IC₅₀s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and *mTOR, respectively. Bimiralisib is an mTORC1* and *mTORC2* inhibitor.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2517

Dihydroevocarpine	Alkaloids Classification of Application Fields Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer	mTOR
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the *mTORC1/2* activity .

HY-N0112

Dihydromyricetin 10+ Cited Publications Ampelopsin; Ampeloptin	Infection Flavanonols Structural Classification Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	mTOR Influenza Virus DNA/RNA Synthesis Autophagy
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-N0656A

(+)-Usnic acid 2 Publications Verification	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids lichen Plants Disease Research Fields Cancer	mTOR Bacterial Autophagy
(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of *mTOR, and inhibits mTORC1/2* activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity . (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium .

HY-10219

Rapamycin Maximum Cited Publications 728 Publications Verification Sirolimus; AY-22989	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Source classification Disease Research Endogenous metabolite Disease Research Fields Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* . Rapamycin is an autophagy activator, an immunosuppressant .

HY-N3628

Coronarin A	Hedychium coronarium Koen. Natural Products Plants Zingiberaceae	mTOR Ribosomal S6 Kinase (RSK)
Coronarin A is an orally active natural compound that inhibits *mTORC1* and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research .

HY-N0189

Aloe emodin 1 Publications Verification Rhabarberone; 3-Hydroxymethylchrysazine	Quinones Structural Classification Liliaceae Classification of Application Fields Anthraquinones Source classification Phenols Polyphenols Aloe vera (L.) Burm. f. Plants Disease Research Fields Cancer	mTOR Influenza Virus Apoptosis Autophagy
Aloe emodin (Rhabarberone) is a natural hydroxyanthraquinone with antitumor activities. aloe-emodin can bind with *mTORC2* and inhibit its kinase activity. Aloe emodin exerts antiproliferation effects and induces cellular apoptosis . Aloe emodin also exhibits antiviral activity that against influenza A virus .

HY-18980

Rottlerin 5 Publications Verification Mallotoxin; NSC 56346; NSC 94525	Structural Classification Chalcones Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Euphorbiaceae Plants Disease Research Fields Mallotus philippensis Cancer	PKC Autophagy Apoptosis HIV RABV
Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC₅₀ values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation . Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection .

Cat. No.	Product Name	Chemical Structure

HY-10219S

Rapamycin-d3
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

HY-10219S1

Rapamycin-13C,d3

Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks